08:39 AM EDT, 10/15/2024 (MT Newswires) -- Argenx (ARGX) said Tuesday new data on its treatments Vyvgart and Vyvgart Hytrulo, for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy, or CIDP, showed "rapid, deep and sustained responses" in patients.

The new data was presented at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting and Myasthenia Gravis Foundation of America Scientific Sessions, being held in Savannah, Georgia, this week.

Argenx said Vyvgart showed consistent improvement across various gMG subtypes, with 55% of patients reducing corticosteroid use by 5 mg/day or more and 42% achieving steroid doses of 5 mg/day or less after one year of use. Additionally, Vyvgart Hytrulo improved motor function and muscle strength in CIDP patients, with benefits lasting up to 24 weeks, Argenx said.

Argenx said it is conducting two phase 3 studies focused on seronegative and ocular MG patients and that seronegative gMG patients evaluated in Vyvgart trials experienced consistent and clinically meaningful improvements in symptoms.

Vyvgart also has a "consistent and favorable" safety record with no need for black box warnings, lab monitoring, or vaccinations, the company said.

Price: 549.22, Change: +5.66, Percent Change: +1.04